Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Overview
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
Featured News & Press Releases
Jul 07, 2022: Immuron receives European Patent Notification on drug composition to treat clostridioides difficile associated disease
Jun 28, 2022: Vedanta unveils state-of-the-art manufacturing facility to provide clinical and commercial supply of oral therapies based on defined bacterial consortia
Jun 07, 2022: Seres Therapeutics announces confirmatory results from investigatiol microbiome therapeutic SER-109 ECOSPOR IV open-label study in recurrent C. difficile infection
May 24, 2022: Ferring presents new alyses of efficacy, safety and microbiome composition data at DDW 2022 for RBX2660 its investigatiol microbiota-based live biotherapeutic
May 22, 2022: Seres Therapeutics presents phase III results of SER-109 for recurrent C. Difficile infection at the Digestive Disease Week (DDW) Annual Meeting
May 19, 2022: Adiso Therapeutics’ ADS024 selected for oral presentation at 2022 Digestive Disease Week Annual Meeting
May 12, 2022: Destiny Pharma: World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration
May 10, 2022: Seres Therapeutics to present data on investigatiol microbiome therapeutic SER-109 for recurrent C. difficile infection at the Digestive Disease Week (DDW) Annual Meeting
Apr 28, 2022: Finch Therapeutics announces removal of FDA clinical hold on CP101 IND
Apr 21, 2022: Adiso Therapeutics announces completion of enrollment in a phase 1b study of ADS024 for the Prevention of C. difficile Recurrence
Apr 18, 2022: Lumen Bioscience announces clinical advancement of LMN-201 for C. difficile Infection
Apr 13, 2022: Vedanta Biosciences publishes phase 1a/1b results for lead program VE303 in Cell Host & Microbe nd highlights planned presentations of phase 2 VE303 results
Apr 07, 2022: The second part of the phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Cada
Mar 01, 2022: Finch Therapeutics provides an update on its phase 3 trial of CP101 in Recurrent C. difficile Infection
Mar 01, 2022: Phase 3 CLOVER Trial for Pfizer’s investigatiol Clostridioides Difficile vaccine indicates strong potential effect in reducing duration and severity of disease based on secondary endpoints
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, 2022
Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, 2022